Altria held adjusted EPS growth at 2.8% in Q2 2026, but cigarette pricing beat the volume-and-mix drag by only about $30 million, aggregate share was defended by shifting Marlboro smokers into discount brands, and on! lost ground in the fast-growing nicotine pouch category.
Overview
Altria's second quarter of 2026 is a clean illustration of the arithmetic that now runs the company: raise cigarette prices enough to cover a shrinking number of packs sold, and let share buybacks make up the difference at the per-share line. It worked, but only just. Net revenues (the top line, which for Altria still includes the excise taxes it bills to customers) were $6,111 million, up 0.1% — essentially flat. Reported operating income fell 2.9% to $3,136 million and reported diluted earnings per share fell 2.8% to $1.37, while adjusted diluted EPS — the figure management guides to, which strips out items it considers outside normal operations — rose 2.8% to $1.48.
Two things drove the gap between those directions, and both are worth separating from the underlying business. First, Altria took a $78 million pre-tax charge to consolidate its smokeless-tobacco manufacturing. Second, its stake in brewer Anheuser-Busch InBev (ABI) produced a $114 million non-cash accounting loss. Neither says anything about how many cigarettes or nicotine pouches Altria sold.
Operating margin (on revenues net of excise taxes)
58.6%
61.1%
-2.5 pp
Reported net earnings
$2,298M
$2,378M
-3.4%
Reported diluted EPS
$1.37
$1.41
-2.8%
Adjusted net earnings
$2,480M
$2,433M
+1.9%
Adjusted diluted EPS
$1.48
$1.44
+2.8%
Domestic cigarette shipment volume
15,554M sticks
16,066M sticks
-3.2%
Total cigarette retail share
45.5%
45.2%
+0.3 pp
Oral tobacco shipment volume
181.7M cans
198.6M cans
-8.5%
Oral tobacco retail share
29.0%
32.7%
-3.7 pp
Income from equity investments
$87M
$148M
-41.2%
Reported effective tax rate
21.5%
23.7%
-2.2 pp
Figures from Altria's Form 10-Q for the quarter ended June 30, 2026 (filed July 30, 2026) and the accompanying earnings release. "pp" means percentage points.
Smokeable products: pricing beat volume by a hair
The smokeable segment — cigarettes (mostly Marlboro) plus Black & Mild cigars — is roughly 88% of revenue and effectively all of the profit. Segment net revenues rose 0.7% to $5,392 million, and the 10-Q gives the exact bridge: higher pricing added $309 million, while what Altria calls "volume/cigarette mix" — fewer packs sold and a larger share of those packs being cheap discount brands rather than premium — took away $279 million. The net gain was about $30 million on a $5.4 billion base.
The same squeeze shows up in profit. Segment operating companies income (OCI — segment profit before corporate overhead and intangible amortization) rose just $12 million, or 0.4%, to $2,942 million. Pricing and a $27 million benefit from refunds of duties and taxes on imported cigarettes pushed it up; volume/mix cost $221 million, litigation charges $63 million, and other costs $44 million. Reported segment margin (measured on revenues after excise taxes) fell 1.0 point to 63.1%. On an adjusted basis — excluding the litigation charge — OCI rose 2.4% and margin rose 0.3 points to 64.8%. So the operating margin held, but only after setting the legal bill aside.
The volume detail is where the story gets uncomfortable:
Cigarette volume (millions of sticks)
Q2 2026
Q2 2025
Change
Marlboro
13,389
14,458
-7.4%
Other premium
678
719
-5.7%
Discount (L&M, Basic)
1,487
889
+67.3%
Total domestic cigarettes
15,554
16,066
-3.2%
Contract-manufactured export cigarettes
736
475
+54.9%
Altria's total cigarette retail share rose 0.3 points to 45.5% — but Marlboro's share fell 1.5 points to 39.5% while its discount brands gained 1.9 points to 3.9%. Altria held its overall shelf position by selling more cheap cigarettes and fewer expensive ones. That is not a neutral trade: a discount pack carries a lower price and a lower margin, which is precisely the $279 million revenue drag quantified above. Management attributes the pattern to "continued discretionary income pressures on adult nicotine consumers," and the industry data agrees — the discount category reached 33.8% of all cigarettes sold at retail, up 2.6 points in a year.
Two adjustments matter for judging the volume figure honestly. Stripping out wholesaler inventory movements, Altria estimates its own domestic cigarette volume fell about 4.5% and the industry's fell about 5% — so the reported -3.2% flatters the underlying trend by roughly a point. And the +54.9% jump in contract-manufactured export cigarettes (made for third parties to sell abroad) is a low-margin volume line that does not reflect US consumer demand at all; it is tied to the import/export duty-refund mechanism that also produced the $27 million profit benefit. Management explicitly expects that benefit to be larger in the second half than in the first.
Price increases continued on schedule: Marlboro (excluding Mainline Menthol and 72s Menthol) and L&M went up $0.20 per pack in both January and April 2026.
Oral tobacco: losing share in the one category that's growing
This is the segment that actually deteriorated. Oral tobacco net revenues fell 5.3% to $713 million as lower volume cost $74 million against $31 million of price increases. Reported OCI dropped 23.5% to $381 million, dragged down by the $78 million restructuring charge; excluding it, adjusted OCI still fell 8.0% to $460 million and adjusted margin lost 2.0 points to 66.7%.
Oral tobacco volume (millions of cans)
Q2 2026
Q2 2025
Change
Copenhagen (moist snuff)
85.4
95.9
-10.9%
Skoal (moist snuff)
29.5
34.2
-13.7%
on! (nicotine pouches)
49.9
52.1
-4.2%
Other (Red Seal, Husky)
16.9
16.4
+3.0%
Total
181.7
198.6
-8.5%
The traditional moist-snuff brands are in structural decline, which is not new. What is notable is that on!, Altria's nicotine pouch brand and its designated growth engine, shipped 4.2% fewer cans in a quarter when the pouch category expanded to 59.9% of the entire US oral tobacco market, up 8.1 points year over year. on!'s share of that pouch category was 14.4%, down 1.7 points from a year earlier — though up 1.0 point from the first quarter, which is the one encouraging data point here. Total segment retail share fell 3.7 points to 29.0%.
Read plainly: US consumers are shifting from dip to pouches quickly, and Altria is capturing less of that shift than its incumbency implies. on! PLUS, the higher-nicotine product Altria is counting on, reached 120,000 stores and resumed 12-milligram shipments in Florida, North Carolina and Texas during the quarter, with national expansion planned for Q3 and new flavours across 6-, 9- and 12-milligram strengths in Q4. That is the response, but it is a Q3–Q4 event, not a Q2 result.
The $78 million charge relates to moving USSTC manufacturing from Nashville, Tennessee to a new plant on Altria's existing Hopkinsville, Kentucky campus — $59 million of non-cash asset write-downs and $19 million of employee separation costs, out of roughly $180 million total expected, with completion targeted for the first quarter of 2028. No cash had been paid as of June 30.
Why reported and adjusted EPS moved in opposite directions
The $0.11 gap between reported EPS of $1.37 and adjusted EPS of $1.48 breaks down as: litigation charges $0.05, asset impairment and exit costs (mostly the USSTC move) $0.04, ABI-related special items $0.04, intangible amortization $0.01, less a $0.03 credit from favourable tax items. The tax line is worth a flag in the other direction: Altria's reported effective tax rate fell 2.2 points to 21.5%, helped mainly by the May 2026 effective settlement of its IRS audit for the 2017 tax year. That is a genuine cash benefit, but a one-time one — it flattered reported earnings while the special items depressed them.
The ABI item deserves its own note because it reads as a business deterioration when it is not one. Altria holds roughly 8.1% of ABI and accounts for it on the equity method with a one-quarter lag, meaning ABI's own results flow into Altria's income statement. Reported income from equity investments halved to $87 million from $148 million — but the ABI contribution of $81 million includes a $114 million non-cash dilution loss triggered by ABI share activity that reduced Altria's ownership percentage. Excluding that, the ABI stake contributed more than last year, which is why the same investments show up as a positive in the adjusted earnings bridge. Cronos added $6 million.
Takeaway: Altria cleared its adjusted EPS bar, but the composition is getting harder to defend — the pricing gain in cigarettes exceeded the volume-and-mix drag by only about $30 million, part of the profit bridge came from import/export duty refunds rather than consumer demand, aggregate cigarette share was defended by shifting Marlboro smokers into discount brands, and on! lost share in the fastest-growing nicotine category. Meanwhile the buyback that supports the per-share figure slowed to $55 million from $274 million a year ago. The model still works; the levers are shortening.
Cash, capital returns and the balance sheet
Altria paid $1.8 billion of dividends in the quarter ($1.06 per share declared, up from $1.02) and $3.6 billion in the first half, and generated $3,043 million of operating cash flow over six months versus $2,925 million a year earlier — helped by lower state settlement payments, partly offset by higher tax payments. Dividends remain comfortably covered.
Buybacks did not. Altria repurchased just 0.8 million shares for $55 million at an average $65.11 in Q2, against 4.7 million shares for $274 million in Q2 2025 — an 80% reduction. Only $665 million remains on the $2 billion authorisation, which expires December 31, 2026. Since "fewer shares outstanding" is cited in the filing as a driver of adjusted EPS growth in both the quarter and the half, a repurchase pace this slow makes that contribution progressively thinner unless the Board authorises more.
Total long-term debt was $24.6 billion at quarter end, down from $25.7 billion at December 2025 after repaying approximately $1.1 billion of 4.400% notes at maturity in February. Debt to Consolidated EBITDA (a leverage measure defined in Altria's credit agreement) stood at 1.9x, with $2.4 billion of cash and an undrawn $3.0 billion revolver. Ratings are A3 / BBB+ / BBB+, all stable. Credit quality is not the issue here.
Guidance and outlook
Altria narrowed full-year 2026 adjusted diluted EPS guidance to $5.61–$5.72, raising the bottom of the range. That is growth of 3.5% to 5.5% from the 2025 base of $5.42. CEO Sal Mancuso framed it as reflecting first-half adjusted EPS growth of 4.9% and "confidence in our full-year plan." The guidance still assumes moderated e-vapor industry growth, continued macroeconomic pressure on nicotine consumers, investment in contract manufacturing, and — notably — that NJOY ACE, barred from US sale by an International Trade Commission exclusion order, does not return to market in 2026. NJOY now sits inside the "all other" category again after Altria concluded in Q1 2026 that its e-vapor business no longer met the threshold for separate segment reporting; that category lost $77 million in the quarter, an improvement from a $108 million loss.
Against first-half adjusted EPS of $2.80, the guidance implies $2.81–$2.92 in the second half versus $2.75 a year ago — roughly 2% to 6% growth. Management has told investors where a chunk of that comes from: a larger benefit from cigarette import and export activity than in the first half, now expected to be spread more evenly across Q3 and Q4.
Our own read: the guidance looks attainable, but for reasons that are increasingly mechanical rather than commercial. Price increases still more than offset volume declines, the tax settlement helps, and the import/export refund benefit is explicitly weighted to the second half. What is not improving is the mix — every quarter in which Marlboro drops 7% while discount brands rise 67% narrows the pricing headroom available next year, because the price increases apply to a base that is progressively cheaper. The single variable that could change the medium-term trajectory is whether the on! PLUS national rollout in Q3 and the Q4 flavour extensions actually reverse on!'s share loss in nicotine pouches. If they do, Altria has a growth asset in the only expanding part of US nicotine. If they do not, the company is left managing a declining cigarette base with a shrinking buyback, and the 3–5% adjusted EPS growth pattern becomes harder to repeat each year. Watch on!'s share of the pouch category — 14.4% this quarter, and the sequential +1.0 point is the number to see continue in Q3.